GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 37 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $865 | – | 227 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 3,111,551 | $17,114,000 | 1.62% |
Paradigm Biocapital Advisors LP | 783,445 | $4,309,000 | 0.86% |
Orbimed Advisors | 7,884,870 | $43,367,000 | 0.79% |
Vivo Capital, LLC | 961,359 | $5,287,000 | 0.53% |
EcoR1 Capital, LLC | 1,921,310 | $10,567,000 | 0.36% |
Temasek Holdings (Private) Ltd | 9,901,940 | $54,460,670 | 0.30% |
Capital International, Inc./CA/ | 2,993,695 | $16,465,000 | 0.23% |
Capital International Sarl | 302,182 | $1,662,000 | 0.13% |
FEDERATED HERMES, INC. | 1,298,578 | $7,142,000 | 0.02% |
Schonfeld Strategic Advisors LLC | 257,924 | $1,419,000 | 0.01% |